Full Press Release Details
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
LEXINGTON, Mass., February 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF- ") family of proteins, today announced that Keros' Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences
TD Cowen 45th Annual Healthcare Conference
Date and Time Monday, March 3, 2025 at 9 50 a.m. Eastern time
Link https wsw.com webcast cowen177 kros 2049093
Format Fireside Chat Presentation
Leerink Partners Global Healthcare Conference
Date and Time Monday, March 10, 2025 at 1 40 p.m. Eastern time
Link https wsw.com webcast leerink38 kros 2250987
Format Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https ir.kerostx.com for up to 90 days following the conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF- family of proteins. Keros is a leader in understanding the role of the TGF- family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros' product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros' second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros' most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.